Home » Roche to acquire Carmot Therapeutics for $2.7 bln

Roche to acquire Carmot Therapeutics for $2.7 bln

The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann/File Photo Acquire Licensing Rights

ZURICH, Dec 4 (Reuters) – Pharmaceutical giant Roche (ROG.S) said on Monday it has entered into a definitive agreement to acquire Carmot Therapeutics (CRMO.O), a US company based in Berkeley.

Roche will pay an upfront purchase price of $2.7 billion and will make additional milestone payments of up to $400 million, it said in a statement.

Reporting by Noele Illien, Editing by Rachel More

Our Standards: The Thomson Reuters Trust Principles.

Acquire Licensing Rights, opens new tab